pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.
Company profile
Ticker
PULM
Exchange
Website
CEO
Teofilo Raad
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ruthigen, Inc.
SEC CIK
PULM stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
31 May 24
8-K
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
29 May 24
S-3
Shelf registration
17 May 24
8-K
Regulation FD Disclosure
15 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
10 May 24
424B3
Prospectus supplement
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
Latest ownership filings
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Michelle Siegert
30 Jan 23
4
Margaret Wasilewski
30 Jan 23
4
Teofilo David Raad
30 Jan 23
4
Todd Bazemore
30 Jan 23
4
Michael J Higgins
30 Jan 23
4
Christopher Cabell
30 Jan 23
4
Anand Varadan
30 Jan 23
4
Richard P. Batycky
30 Jan 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.77 mm | 17.77 mm | 17.77 mm | 17.77 mm | 17.77 mm | 17.77 mm |
Cash burn (monthly) | 957.67 k | 1.22 mm | (no burn) | 784.00 k | 906.33 k | 1.15 mm |
Cash used (since last report) | 2.72 mm | 3.46 mm | n/a | 2.23 mm | 2.57 mm | 3.26 mm |
Cash remaining | 15.05 mm | 14.31 mm | n/a | 15.54 mm | 15.20 mm | 14.51 mm |
Runway (months of cash) | 15.7 | 11.8 | n/a | 19.8 | 16.8 | 12.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 1 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 815.15 mm |
Total shares | 4.67 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 2.46 mm | $0.00 |
FiveT Investment Management | 928.94 k | $1.87 mm |
Arch Venture Fund VII | 458.65 k | $436.00 k |
Bigger Capital Fund L P | 295.79 k | $266.00 k |
Sabby Management | 184.07 k | $493.32 mm |
Renaissance Technologies | 109.01 k | $292.00 k |
Intracoastal Capital | 100.32 k | $0.00 |
BLK Blackrock | 54.90 k | $147.13 mm |
Geode Capital Management | 24.62 k | $65.99 mm |
Vanguard | 21.39 k | $57.33 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 23 | Michelle Siegert | Stock Option Common Stock | Grant | Acquire A | No | No | 3.99 | 9,900 | 39.50 k | 9,900 |
26 Jan 23 | Margaret Wasilewski | Stock Option Common Stock | Grant | Acquire A | No | No | 3.99 | 11,400 | 45.49 k | 11,400 |
26 Jan 23 | Raad Teofilo David | Stock Option Common Stock | Grant | Acquire A | No | No | 3.99 | 34,900 | 139.25 k | 34,900 |
26 Jan 23 | Bazemore Todd | Stock Option Common Stock | Grant | Acquire A | No | No | 3.99 | 1,700 | 6.78 k | 1,700 |
26 Jan 23 | Michael J Higgins | Stock Option Common Stock | Grant | Acquire A | No | No | 3.99 | 2,436 | 9.72 k | 2,436 |
Press releases
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
29 May 24
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
15 May 24
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
10 May 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
28 Mar 24